Antiviral and Antibiotic Prescribing for Influenza in Primary Care
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Anti-influenza antiviral medications reduce influenza-related morbidity, but may often be used inappropriately.
To measure the rate of antiviral and antibiotic prescribing, the appropriateness of antiviral prescribing, and evaluate independent predictors of antiviral and antibiotic prescribing for influenza in primary care.
DESIGN AND PATIENTS
Retrospective analysis of 958 visits of clinician-diagnosed influenza in 21 primary care clinics in eastern Massachusetts from 1999 to 2007. We considered antiviral prescribing appropriate if patients had symptoms for 2 or fewer days, had fever, and any 2 of headache, sore throat, cough, or myalgias.
MEASUREMEMTS AND MAIN RESULTS
Clinicians prescribed antivirals in 557 (58%) visits and antibiotics in 104 visits (11%). Of antiviral prescriptions, 38% were not appropriate, most commonly because of symptoms for more than 2 days (24% of antiviral prescriptions). In multivariate modeling, selected independent predictors of antiviral prescribing were symptom duration of 2 or fewer days (odds ratio [OR], 12.4; 95% confidence interval [CI], 8.3 to 18.6), year (OR, 1.4 for each successive influenza season; 95% CI, 1.3 to 1.7), patient age (OR, 1.3 per decade; 95% CI, 1.2 to 1.5), and, compared to having no influenza testing, having a negative influenza test (OR, 5.5; 95% CI, 3.4 to 9.1) or a positive influenza test (OR, 11.4; 95% CI, 6.7 to 19.3). Independent predictors of antibiotic prescribing included otoscopic abnormalities (OR, 3.3; 95% CI, 1.8 to 6.0), abnormal lung examination (OR, 4.0; 95% CI, 2.1 to 6.2), and having a chest x-ray performed (OR, 2.2; 95% CI, 1.3 to 3.8).
Primary care clinicians are much more likely to prescribe antivirals to patients with symptoms for 2 or fewer days, but also commonly prescribe antivirals inappropriately.
- Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR. 2007;56(RR-6):1–54.
- Glezen WP. Prevention and treatment of seasonal influenza. New Engl J Med. 2008;359(24):2579–2585. CrossRef
- Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med. 2001;161(2):212–217. CrossRef
- Libow LS, Neufeld RR, Olson E, Breuer B, Starer P. Sequential outbreak of influenza A and B in a nursing home: efficacy of vaccine and amantadine. J Am Geriatr Soc. 1996;44(10):1153–1157.
- Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999–2000. J Am Geriatr Soc. 2002;50(4):608–616. CrossRef
- Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med. 2003;139:321–329.
- Rothberg MB, He S, Rose DN. Management of influenza symptoms in healthy adults: cost-effectiveness of rapid testing and antiviral therapy. J Gen Intern Med. 2003;18:808–815. CrossRef
- Barr CE, Schulman K, Iacuzio D, Bradley JS. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. Curr Med Res Opin. 2007;23(3):523–531. CrossRef
- McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45(12):1568–1575. CrossRef
- Linder JA, Bates DW, Platt R. Antivirals and antibiotics for influenza in the United States, 1995–2002. Pharmacoepidemiol Drug Saf. 2005;14(8):531–536. CrossRef
- Linder JA, Chan JC, Bates DW. Appropriateness of antiviral prescribing for influenza in primary care: a retrospective analysis. J Clin Pharm Ther. 2006;31(3):245–252. CrossRef
- Cole JA, Loughlin JE, Ajene AN, Rosenberg DM, Cook SE, Walker AM. The effect of zanamivir treatment on influenza complications: a retrospective cohort study. Clin Ther. 2002;24(11):1824–1839. CrossRef
- Gums JG, Pelletier EM, Blumentals WA. Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children. Expert Opin Pharmacother. 2008;9(2):151–161. CrossRef
- Blumentals WA, Schulman KL. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study. Curr Med Res Opin. 2007;23(12:)2961–2970. CrossRef
- Cox F, Khan ZM, Schweinle JE, Okamoto L, McLaughlin T. Cost associated with the treatment of influenza in a managed care setting. MedGenMed. 2000;2(4):E34.
- Murphy SN, Chueh HC. A security architecture for query tools used to access large biomedical databases. AMIA Annu Symp Proc. 2002:552–556.
- Two neuraminidase inhibitors for treatment of influenza. Med Lett Drugs Ther. 1999;41(1063):91–93.
- Rapid diagnostic tests for influenza. Med Lett Drugs Ther. 1999;41(1068):121–122.
- Linder JA, Bates DW, Williams DH, Connolly MA, Middleton B. Acute infections in primary care: accuracy of electronic diagnoses and electronic antibiotic prescribing. J Am Med Inform Assoc. 2006;13(1):61–66. CrossRef
- Centers for Disease Control and Prevention. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents — United States, 2005–2006 influenza season. MMWR. 2006;55(2):44–46.
- The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet. 1998;352(9144):1877–1881. CrossRef
- Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis. 1999;180(2):254–261. CrossRef
- Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000;160(21):3243–3247. CrossRef
- Zambon M, Hays J, Webster A, Newman R, Keene O. Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Arch Intern Med. 2001;161(17):2116–2122. CrossRef
- Centers for Disease Control and Prevention. Flu Activity & Surveillance. Available at: http://www.cdc.gov/flu/weekly/fluactivity.htm. Accessed January 12, 2009.
- Falsey AR, Murata Y, Walsh EE. Impact of rapid diagnosis on management of adults hospitalized with influenza. Arch Intern Med. 2007;167(4):354–360. CrossRef
- Linder JA. Improving care for acute respiratory infections: better systems, not better microbiology. Clin Infect Dis. 2007;45(9):1189–1191. CrossRef
- Antiviral and Antibiotic Prescribing for Influenza in Primary Care
Journal of General Internal Medicine
Volume 24, Issue 4 , pp 504-510
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- influenza, human
- antiviral agents
- antibacterial agents
- drug utilization
- Industry Sectors
- Author Affiliations
- 1. Division of General Medicine and Primary Care, Brigham and Women’s Hospital, 1620 Tremont Street, BC-3-2X, Boston, MA, 02120, USA
- 2. Harvard Medical School (JAL), Boston, MA, USA
- 3. Roche Pharmaceuticals (WAB), Nutley, NJ, USA